INTERCEPT PHARMACEUTICALS INC 4

4 · INTERCEPT PHARMACEUTICALS INC · Filed Jul 8, 2015

Insider Transaction Report

Form 4
Period: 2015-07-06
Adorini Luciano
Chief Scientific Officer
Transactions
  • Sale

    Common Stock

    2015-07-06$238.64/sh367$87,58013,809 total
  • Sale

    Common Stock

    2015-07-06$241.57/sh1,000$241,57111,609 total
  • Exercise/Conversion

    Common Stock

    2015-07-06$21.50/sh+4,000$86,00014,776 total
  • Exercise/Conversion

    Option to Purchase Common Stock

    2015-07-06670 total
    Exercise: $8.67Exp: 2021-10-13Common Stock (67 underlying)
  • Sale

    Common Stock

    2015-07-06$2538.02/sh600$1,522,81514,176 total
  • Sale

    Common Stock

    2015-07-06$241.81/sh770$186,19410,839 total
  • Sale

    Common Stock

    2015-07-06$240.63/sh1,200$288,75212,609 total
  • Exercise/Conversion

    Option to Purchase Common Stock

    2015-07-064,0002,923 total
    Exercise: $21.50Exp: 2022-11-16Common Stock (4,000 underlying)
  • Exercise/Conversion

    Common Stock

    2015-07-06$8.67/sh+67$58110,776 total
  • Sale

    Common Stock

    2015-07-06$243.69/sh130$31,68010,709 total
Footnotes (8)
  • [F1]The reported transaction was made pursuant to a 10(b)5-1 plan adopted by the reporting person on March 9, 2015.
  • [F2]All the shares underlying this option have fully vested.
  • [F3]The remaining shares underlying this option vest on a pro rata monthly basis through January 1, 2016, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan.
  • [F4]This transaction was executed in multiple trades at prices ranging from $237.52 to $238.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F5]This transaction was executed in multiple trades at prices ranging from $238.55 to $238.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F6]This transaction was executed in multiple trades at prices ranging from $240.00 to $240.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F7]This transaction was executed in multiple trades at prices ranging from $241.0150 to $242.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F8]This transaction was executed in multiple trades at prices ranging from $242.3200 to $242.9600. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Documents

1 file
  • 4
    v415115_4.xmlPrimary

    OWNERSHIP DOCUMENT